Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies

被引:33
作者
de Mello, Ramon Andrade [1 ,2 ]
Marques, Dania Sofia [1 ]
Medeiros, Rui [3 ,4 ]
Araujo, Antonio M. F. [5 ]
机构
[1] Portuguese Oncol Inst, Dept Med Oncol, Rua Dr Antonio Bernadino Almeida S-N, P-4200072 Porto, Portugal
[2] Univ Porto, Fac Med, Dept Med 2, Discipline Clin Semiot, P-4200319 Porto, Portugal
[3] IPOPFG, Mol Oncol Unit CI, P-4200072 Porto, Portugal
[4] Univ Porto, IC BAS, Dept Mol Immunol & Pathol 2, P-4099003 Porto, Portugal
[5] Portuguese Oncol Inst, Dept Med Oncol, Lung Clin, P-4200072 Porto, Portugal
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 2卷 / 11期
关键词
Epidermal growth factor receptor; K-Ras; Non-small-cell lung carcinoma; Pharmacogenomics; p21ras proto-oncogene proteins;
D O I
10.5306/wjco.v2.i11.367
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is currently the leading cause of cancer death in Western nations. Non-small cell lung cancer (NSCLC) represents 80% of all lung cancers, and adenocarcinoma is the predominant histological type. Despite the intensive research carried out on this field and therapeutic advances, the overall prognosis of these patients remains unsatisfactory, with a 5-year overall survival rate of less than 15%. Nowadays, pharmacogenetics and pharmacogenomics represent the key to successful treatment. Recent studies suggest the existence of two distinct molecular pathways in the carcinogenesis of lung adenocarcinoma: one associated with smoking and activation of the K-Ras oncogene and the other not associated with smoking and activation of the epidermal growth factor receptor (EGFR). mutation is mainly responsible for primary resistance to new molecules which inhibit tyrosine kinase EGFR (erlotinib and gefitinib) and most of the EGFR mutations are responsible for increased tumor sensitivity to these drugs. This article aims to conduct a systematic review of the literature regarding the molecular pathways involving the EGFR, K-Ras and EGFR targeted therapies in NSCLC tumor behavior. (C) 2011 Baishideng. All rights reserved.
引用
收藏
页码:367 / 376
页数:10
相关论文
共 102 条
[1]   Blocking oncogenic Ras signaling for cancer therapy [J].
Adjei, AA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074
[2]   Epidemiology of lung cancer: Looking to the future [J].
Alberg, AJ ;
Brock, MV ;
Samet, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3175-3185
[3]   Acquired somatic mutations in the molecular pathogenesis of COPD [J].
Anderson, GP ;
Bozinovski, S .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (02) :71-76
[4]   Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development [J].
不详 .
CURRENT PROBLEMS IN CANCER, 2009, 33 (02) :73-111
[5]  
[Anonymous], 2010, AM J CLIN PATHOL, DOI DOI 10.1309/AJCPST1CTHZS3PSZ
[6]  
[Anonymous], 2010, J CLIN ONCOL, DOI DOI 10.1200/JCO.2010.28.15_SUPPL.3017
[7]   Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer -: A review of the literature [J].
Araujo, Antonio ;
Ribeiro, Ricardo ;
Azevedo, Isabel ;
Coelho, Ana ;
Soares, Marta ;
Sousa, Berta ;
Pinto, Daniela ;
Lopes, Carlos ;
Medeiros, Rui ;
Scagliotti, Giorgio V. .
ONCOLOGIST, 2007, 12 (02) :201-210
[8]   Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of national cancer institute of Canada clinical trials group trials [J].
Asmis, Timothy R. ;
Ding, Keyue ;
Seymour, Lesley ;
Shepherd, Frances A. ;
Leighl, Natasha B. ;
Winton, Tim L. ;
Whitehead, Marlo ;
Spaans, Johanna N. ;
Graham, Barbara C. ;
Goss, Glenwood D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) :54-59
[9]   K-ras mutations in non-small-cell lung carcinoma:: A review [J].
Aviel-Ronen, Sarit ;
Blackhall, Fiona H. ;
Shepherd, Frances A. ;
Tsao, Ming-Sound .
CLINICAL LUNG CANCER, 2006, 8 (01) :30-38
[10]   RAS ONCOGENES - THEIR ROLE IN NEOPLASIA [J].
BARBACID, M .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1990, 20 (03) :225-235